Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Quest Diagnostics To Sell HemoCue Diagnostic Products Business For $300 Mln

RELATED NEWS
Trade DGX now with 

Quest Diagnostics (DGX: Quote), a provider of diagnostic information services, Monday said it has signed a definitive agreement to sell its HemoCue diagnostic products business to Radiometer Medical ApS for around $300 million plus customary adjustments for cash balances.

HemoCue develops, produces and markets hemoglobin, glucose and other point-of-care testing systems worldwide.

Steve Rusckowski, President and CEO of Quest Diagnostics, said, "The HemoCue divestiture, along with our sale of OralDNA in December 2012, demonstrates our commitment to refocus our business on diagnostic information services."

Quest plans to use the proceeds to repurchase around $300 million of its shares as part of its stock buyback program.

The transaction is expected to be completed in March.

Click here to receive FREE breaking news email alerts for Quest Diagnostics and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After showing a notable move to the upside in early trading on Tuesday, stocks showed a substantial downturn over the course of the session. Concerns about the impact of new sanctions against Russia weighed on the markets. A day after lawmakers announced an agreement on compromise legislation to reform the Veterans Affairs Department, the Senate voted unanimously Tuesday to confirm a new head of the scandal-plagued department. Looking to increase pressure on Congress, the White House released a report on Tuesday warning of the economic costs of delaying action to address climate change.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.